Lymphangioleiomyomatosis and mTOR inhibitors in real world-a narrative review.

ABSTRACT:

Background and objective

Lymphangioleiomyomatosis (LAM) is a rare disease developing mostly on lung and leading to various pulmonary and extra-pulmonary manifestations. Management of this intractable illness has been mostly symptomatic and supplementary until the advent and application of a novel drug, i.e., the mechanistic target of rapamycin (mTOR) inhibitor, and successful disease control using mTOR inhibitors is improving LAM patients. Although mTOR inhibitors are showing remarkable results there are still many rooms for further progress, and partly solved issues on problems seen in LAM still remain. We searched multiple reports and investigational studies regarding LAM, especially the therapeutic achievement won by mTOR inhibitors. This article summarized several characteristi

SUBMITTER: Park S 

PROVIDER: S-EPMC10713282 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature